Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 23;38(35):4184–4193. doi: 10.1200/JCO.20.01276

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by American Society of Clinical Oncology

PMC Copyright notice

FIG 1. — Kaplan-Meier curves for relapse-free survival (RFS) and overall survival (OS) in the intention-to-treat (ITT) population. (A) Kaplan-Meier estimates of RFS at 7 years by treatment arm in the ITT population, showing a significant benefit of THL (paclitaxel, trastuzumab, and lapatinib) versus TH (paclitaxel plus trastuzumab) treatment arms. (B) Kaplan-Meier estimates of OS at 7 years by treatment arm in the ITT population, showing a significant benefit of THL versus TH treatment arms. (C) Kaplan-Meier estimates of RFS at 7 years by pathologic complete response (pCR) status in the ITT population, showing a significant improvement in outcome in pCR versus residual disease (RD). (D) Kaplan-Meier estimates of OS at 7 years by pCR status in the ITT population, showing a significant improvement in outcome in pCR versus RD. HR, hazard ratio; TL, paclitaxel and lapatinib.